# US 8,785,393 B2 · Ophthalmic pharmaceutical compositions of DP2 receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,393 B2
- Document ID: US8785393B2
- Status: Granted
- Kind: B2
- Application number: 13/387,064
- Filed: 2010-07-28
- Published: 2012-07-19
- Granted: 2014-07-22
- Earliest claimed: 2009-07-31
- Assignees: Panmira Pharmaceuticals, LLC
- Applicants: John Howard Hutchinson; Thomas Jon Seiders; Nicholas Simon Stock
- Inventors: John Howard Hutchinson; Thomas Jon Seiders; Nicholas Simon Stock
- Web page: https://patentgrep.com/patent/US8785393B2

## CPC

- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP2 receptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.

## Claims

### Claim 1

A method of treating an ophthalmic disease or condition in a mammal comprising topically administering an ophthalmic pharmaceutical composition comprising a DP2 receptor antagonist compound and at least one pharmaceutically acceptable excipient to the eyes of the mammal, wherein the DP2 receptor antagonist compound is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof:
wherein,
each of R2, R3, and R4 is independently H, F, Cl, Br, I, —CN, —C1-C6alkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6alkoxy, or C1-C6heteroalkyl;
R6 is F, Cl, Br, I, —CN, —NO2, —OH, —O(C1-C6alkyl), —S(═O)2R12, —N(C1-C4alkyl)S(═O)2R12, —NHS(═O)2R12, —S(═O)2N(R13)2, —C(═O)R12, —CO2(C1-C6alkyl), —NH2, —C(═O)NH(R13), —C(═O)N(R13)2, —OC(═O)NH(R13), —OC(═O)N(R13)2, —N(C1-C4alkyl)C(═O)N(R13)2, —NHC(═O)N(R13)2, —NHC(═O)NH(R13), —N(C1-C4alkyl)C(═O)R12, —NHC(═O)R12, —NH—C1-C4alkyl-C(═O)R12, —N(C1-C4alkyl)C(═O)OR12, —NHC(═O)OR12, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6heteroalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic or bicyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S;
R11 is C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic or bicyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S, a substituted or unsubstituted —C1-C6alkyl-phenyl, —C1-C6alkylene-N(R17)2, —C1-C6alkylene-C(═O)O—R17, or —C1-C6alkylene-C(═O)N(R17)2; R17 is H, or C1-C6alkyl;
R12 is C1-C6alkyl, C1-C6heteroalkyl, C1-C6fluoroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S, a substituted or unsubstituted —C1-C4alkyl-C3-C10cycloalkyl, a substituted or unsubstituted —C1-C4 alkyl-phenyl, or a substituted or unsubstituted —C1-C4alkyl-(monocyclic heteroaryl containing 0 to 3 heteroatoms selected from N, O or S);
each R13 is independently selected from H, C1-C6alkyl, C1-C6 heteroalkyl, C1-C6fluoroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S, a substituted or unsubstituted —C1-C4alkyl-C3-C10cycloalkyl, a substituted or unsubstituted —C1-C4alkyl-C2-C10heterocycloalkyl, a substituted or unsubstituted —C1-C4alkyl-phenyl, and a substituted or unsubstituted —C1-C4alkyl-(monocyclic heteroaryl containing 0 to 3 heteroatoms selected from N, O or S); or
two R13 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted C2-C10heterocycloalkyl; and
Y is —S—, —S(═O)—, or —S(═O)2—.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ophthalmic pharmaceutical composition is in a form suitable for administration to the eyes of a mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ophthalmic pharmaceutical composition compound is in the form of an ophthalmic solution, ophthalmic suspension, ophthalmic drops, ophthalmic emulsion, ophthalmic ointment, ophthalmic gel or an ophthalmic insert.

### Claim 4 (depends on 2)

The method of claim 2, wherein the ophthalmic pharmaceutical composition is administered to the eye of the mammal via implantation, insertion, injection, spraying, washing, or combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ophthalmic disease or condition is an immune disorder; a proliferation disorder; contact with an allergen and/or an irritant; a mast cell mediated disease or condition; a Th2 lymphocyte mediated disease or condition; an infection, or combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ophthalmic disease or condition is age-related macular degeneration, allergic conjunctivitis, eosinophilic keratitis, anterior segment scarring, blepharitis, blepharoconjunctivitis, a bullous disorder, cicatricial pemphigoid, conjunctival melanoma, conjunctivitis, contact lens-associated giant papillary conjunctivitis, diabetic retinopathy, dry eye, episcleritis, glaucoma, gliosis, granuloma annulare, Graves' ophthalmopathy, intraocular melanoma, keratitis, keratoconjunctivitis, pain, pinguecula, post-surgical pain, proliferative vitreoretinopathy, pterygia, scarring, scleritis, Sjögren's syndrome, uveitis, vernal keratoconjunctivitis or combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ophthalmic disease or condition is ocular itching or ocular inflammation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ophthalmic disease or condition comprises redness, irritation, swelling, lachrymal secretions, or a combination thereof in the eye of a mammal.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method comprises administering a second therapeutic agent to the mammal.

### Claim 10 (depends on 9)

The method of claim 9, wherein the second therapeutic agent is an antibiotic, an anti-fungal agent, a steroid anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an antiviral agent, an alpha agonist, a beta blocker, a carbonic anhydrase inhibitor, a prostaglandin, an anti-angiogenesis agent, loteprednol etabonate, a mast cell stabilizer, cyclosporine, or a leukotriene modulator.

### Claim 11 (depends on 9)

The method of claim 9, wherein the second therapeutic agent is a leukotriene modulator selected from 5-lipoxygenase (5-LO) inhibitors, 5-lipoxygenase activating protein (FLAP) inhibitors, and leukotriene receptor antagonists.

### Claim 12

An ophthalmic pharmaceutical composition comprising a DP2 receptor antagonist compound and at least one pharmaceutically acceptable excipient to provide a solution suspension drop, emulsion, ointment, gel or an insert; wherein the ophthalmic pharmaceutical composition is in a form suitable for administration to an eye of a mammal; wherein at least one pharmaceutically acceptable excipient is selected from a pH adjusting component, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient, or combination thereof; and wherein the DP2 receptor antagonist compound is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof:
wherein,
each of R2, R3, and R4 is independently H, F, Cl, Br, I, —CN, —C1-C6alkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6alkoxy, or C1-C6heteroalkyl;
R6 is F, Cl, Br, I, —CN, —NO2, —OH, —O(C1-C6alkyl), —S(═O)2R12, —N(C1-C4alkyl)S(═O)2R12, —NHS(═O)2R12, —S(═O)2N(R13)2, —C(═O)R12, —CO2(C1-C6alkyl), —NH2, —C(═O)NH(R13), —C(═O)N(R13)2, —OC(═O)NH(R13), —OC(═O)N(R13)2, —N(C1-C4alkyl)C(═O)N(R13)2, —NHC(═O)N(R13)2, —NHC(═O)NH(R13), —N(C1-C4alkyl)C(═O)R12, —NHC(═O)R12, —NH—C1-C4alkyl-C(═O)R12, —N(C1-C4alkyl)C(═O)OR12, —NHC(═O)OR12, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6fluoroalkoxy, C1-C6heteroalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic or bicyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S;
R11 is C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic or bicyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S, a substituted or unsubstituted —C1-C4alkyl-phenyl, —C1-C6alkylene-N(R17)2, —C1-C6alkylene-C(═O)O—R17, or —C1-C6alkylene-C(═O)N(R17)2; R17 is H, or C1-C6alkyl;
R12 is C1-C6alkyl, C1-C6heteroalkyl, C1-C6fluoroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S, a substituted or unsubstituted —C1-C4alkyl-C3-C10cycloalkyl, a substituted or unsubstituted —C1-C4alkyl-phenyl, or a substituted or unsubstituted —C1-C4alkyl-(monocyclic heteroaryl containing 0 to 3 heteroatoms selected from N, O or S);
each R13 is independently selected from H, C1-C6alkyl, C1-C6heteroalkyl, C1-C6fluoroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl containing 0-3 heteroatoms selected from N, O or S, a substituted or unsubstituted —C1-C4alkyl-C3-C10cycloalkyl, a substituted or unsubstituted —C1-C4alkyl-C2-C10heterocycloalkyl, a substituted or unsubstituted —C1-C4alkyl-phenyl, and a substituted or unsubstituted —C1-C4alkyl-(monocyclic heteroaryl containing 0 to 3 heteroatoms selected from N, O or S); or
two R13 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted C2-C10heterocycloalkyl; and
Y is —S—, —S(═O)—, or —S(═O)2—.

### Claim 13 (depends on 12)

The ophthalmic pharmaceutical composition of claim 12, wherein:
R2 is H;
R3 is H;
R4 is H, halogen, —CN, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4fluoroalkoxy, C1-C4alkoxy, or C1-C4heteroalkyl;
R6 is —N(C1-C4alkyl)S(═O)2R12, —NHS(═O)2R12, —S(═O)2N(R13)2, —NH2, —C(═O)NH(R13), —C(═O)N(R13)2, —N(C1-C4alkyl)C(═O)N(R13)2, —NHC(═O)N(R13)2, —NHC(═O)NH(R13), —N(C1-C4alkyl)C(═O)R12, —NHC(═O)R12, —N(C1-C4alkyl)C(═O)OR12, or —NHC(═O)OR12;
R11 is C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted 5-membered heteroaryl, a substituted or unsubstituted 6-membered heteroaryl, or —C1-C4alkyl-(substituted or unsubstituted phenyl);
R12 is C1-C6alkyl, C1-C6heteroalkyl, C1-C6fluoroalkyl, C3-C6cycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted 6-membered heteroaryl, or —C1-C4alkyl-(substituted or unsubstituted phenyl); and
R13 is H or C1-C4alkyl.

### Claim 14 (depends on 13)

The ophthalmic pharmaceutical composition of claim 13, wherein:
R6 is —N(C1-C4alkyl)C(═O)R12 or —NHC(═O)R12;
R11 is C1-C6alkyl, C1-C6haloalkyl, a substituted or unsubstituted phenyl, or —C1-C4alkyl-(substituted or unsubstituted phenyl); and
R12 is C1-C6alkyl, C3-C6cycloalkyl, or a substituted or unsubstituted phenyl.

### Claim 15 (depends on 14)

The ophthalmic pharmaceutical composition of claim 14, wherein:
R4 is F, Cl, —OCH3, —CF3, or —OCF3;
R11 is —C(CH3)3; and
R12 is —C(CH3)3.

### Claim 16 (depends on 12)

The ophthalmic pharmaceutical composition of claim 12, wherein the DP2 receptor antagonist compound is {3-[2-tert-butylsulfanylmethyl-4-(2,2-dimethyl-propionylamino)-phenoxy]-4-methoxy-phenyl}-acetic acid, or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 12)

The ophthalmic pharmaceutical composition of claim 12, wherein the ophthalmic pharmaceutical composition further comprises a tonicity adjusting component.

### Claim 18 (depends on 17)

The ophthalmic pharmaceutical composition of claim 17, wherein the tonicity adjusting component is sodium borate, boric acid, sodium chloride, potassium chloride, mannitol, dextrose, glycerin, propylene glycol or mixtures thereof.

### Claim 19 (depends on 12)

The ophthalmic pharmaceutical composition of claim 12, wherein the concentration of the DP2 receptor antagonist compound in the ophthalmic pharmaceutical composition is about 0.1% to about 10% by weight of the ophthalmic pharmaceutical composition.

### Claim 20 (depends on 12)

The ophthalmic pharmaceutical composition of claim 12, wherein the ophthalmic pharmaceutical composition is used for treating an ophthalmic disease or condition selected from an immune disease or condition; a proliferative disease or condition; contact with an allergen and/or an irritant; a mast cell mediated disease or condition; a Th2 lymphocyte mediated disease or condition; an infection or combinations thereof.

### Claim 21 (depends on 12)

The ophthalmic pharmaceutical composition of claim 12, wherein the ophthalmic pharmaceutical composition is used for treating age-related macular degeneration, allergic conjunctivitis, eosinophilic keratitis, anterior segment scarring, blepharitis, blepharoconjunctivitis, a bullous disorder, cicatricial pemphigoid, conjunctival melanoma, conjunctivitis, contact lens-associated giant papillary conjunctivitis, diabetic retinopathy, dry eye, episcleritis, glaucoma, gliosis, granuloma annulare, Graves' ophthalmopathy, intraocular melanoma, keratitis, keratoconjunctivitis, pain, pinguecula, post-surgical pain, proliferative vitreoretinopathy, pterygia, scarring, scleritis, Sjögren's syndrome, uveitis, vernal keratoconjunctivitis or combinations thereof.

### Claim 22 (depends on 1)

The method of claim 1, wherein the DP2 receptor antagonist compound is {3- [2-tert-butylsulfanylmethyl-4-(2,2-dimethyl-propionylamino)-phenoxy]-4-methoxy-phenyl}- acetic acid, or a pharmaceutically acceptable salt thereof.
